Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTANASDAQ:CORINASDAQ:IDYANASDAQ:SUPN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$12.68+0.6%$12.68$8.46▼$19.09$1.69B1.48713,894 shs1.38 million shsCORICorium International$12.68$0.00$7.17▼$13.93$459.65M0.87577,723 shsN/AIDYAIDEAYA Biosciences$21.86-0.3%$19.47$13.45▼$44.42$1.91B0.041.03 million shs1.05 million shsSUPNSupernus Pharmaceuticals$32.96+1.9%$32.13$25.55▼$40.28$1.85B0.71485,204 shs583,113 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals+0.63%+1.52%+3.43%-22.16%+48.91%CORICorium International0.00%0.00%0.00%0.00%0.00%IDYAIDEAYA Biosciences-0.27%-0.27%+20.91%+18.55%-41.35%SUPNSupernus Pharmaceuticals+1.95%-0.57%-0.27%+1.98%+23.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNTACentessa Pharmaceuticals3.5467 of 5 stars4.52.00.00.02.03.30.6CORICorium InternationalN/AN/AN/AN/AN/AN/AN/AN/AIDYAIDEAYA Biosciences3.7759 of 5 stars3.52.00.04.42.21.70.0SUPNSupernus Pharmaceuticals1.4039 of 5 stars1.21.00.04.11.80.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTACentessa Pharmaceuticals 3.00Buy$27.89119.94% UpsideCORICorium International 0.00N/AN/AN/AIDYAIDEAYA Biosciences 2.93Moderate Buy$54.27148.27% UpsideSUPNSupernus Pharmaceuticals 2.33Hold$36.009.22% UpsideCurrent Analyst Ratings BreakdownLatest CORI, SUPN, IDYA, and CNTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025CNTACentessa PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.005/22/2025IDYAIDEAYA BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $66.005/8/2025CNTACentessa PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform ➝ Outperform$6.005/8/2025CNTACentessa PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.003/31/2025CNTACentessa PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$38.003/26/2025CNTACentessa PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTACentessa Pharmaceuticals$6.85M247.21N/AN/A$3.05 per share4.16CORICorium International$31.86M14.43N/AN/A$0.45 per share28.18IDYAIDEAYA Biosciences$7M273.50N/AN/A$12.25 per share1.78SUPNSupernus Pharmaceuticals$661.82M2.79$4.17 per share7.90$18.76 per share1.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTACentessa Pharmaceuticals-$235.76M-$1.81N/AN/AN/AN/A-40.22%-29.95%8/12/2025 (Estimated)CORICorium International-$47.79M-$1.64N/AN/AN/A-155.21%-276.89%-57.52%N/AIDYAIDEAYA Biosciences-$274.48M-$3.59N/AN/AN/AN/A-29.28%-27.68%8/5/2025 (Estimated)SUPNSupernus Pharmaceuticals$73.86M$1.1129.6922.89N/A9.27%12.23%9.17%8/5/2025 (Estimated)Latest CORI, SUPN, IDYA, and CNTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025CNTACentessa Pharmaceuticals-$0.35-$0.20+$0.15-$0.20N/AN/A5/6/2025Q1 2025IDYAIDEAYA Biosciences-$0.75-$0.82-$0.07-$0.82$2.10 millionN/A3/24/2025Q4 2024CNTACentessa Pharmaceuticals-$0.38-$0.34+$0.04-$0.84N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTACentessa PharmaceuticalsN/AN/AN/AN/AN/ACORICorium InternationalN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/ASUPNSupernus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTACentessa Pharmaceuticals0.2814.3714.37CORICorium International2.837.617.47IDYAIDEAYA BiosciencesN/A13.9213.92SUPNSupernus PharmaceuticalsN/A2.442.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTACentessa Pharmaceuticals82.01%CORICorium InternationalN/AIDYAIDEAYA Biosciences98.29%SUPNSupernus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCNTACentessa Pharmaceuticals7.09%CORICorium International30.80%IDYAIDEAYA Biosciences2.50%SUPNSupernus Pharmaceuticals8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTACentessa Pharmaceuticals200133.55 million124.09 millionOptionableCORICorium InternationalN/A36.25 millionN/AOptionableIDYAIDEAYA Biosciences8087.58 million85.39 millionOptionableSUPNSupernus Pharmaceuticals58055.99 million51.06 millionOptionableCORI, SUPN, IDYA, and CNTA HeadlinesRecent News About These CompaniesSAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGEJune 18 at 11:03 PM | businesswire.comSupernus Pharma to Buy Sage Therapeutics for Up to $795 MillionJune 17 at 12:40 AM | marketwatch.comSupernus enters depression drug market with up to $795 million Sage dealJune 17 at 12:40 AM | msn.comSupernus to acquire depression drugmaker SageJune 17 at 12:40 AM | msn.comSupernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage TherapeuticsJune 17 at 12:40 AM | msn.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.June 16 at 5:31 PM | prnewswire.comSupernus Pharmaceuticals (SUPN) to Acquire Sage Therapeutics in $795M DealJune 16 at 8:52 AM | gurufocus.comSupernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry ...June 16 at 8:52 AM | gurufocus.comSupernus Pharmaceuticals to Acquire Sage Therapeutics in a Strategic Move | SUPN stock newsJune 16 at 8:51 AM | gurufocus.comSage Therapeutics Stock Soars 35% After Sale to Supernus Pharmaceuticals. What We Know.June 16 at 8:26 AM | barrons.comSupernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry ...June 16 at 7:56 AM | gurufocus.comSupernus Pharma to acquire Sage Therapeutics in up to $795 million dealJune 16 at 7:14 AM | reuters.comSupernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product PortfolioJune 16 at 7:00 AM | globenewswire.comAzzad Asset Management Inc. ADV Acquires New Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 16 at 4:15 AM | marketbeat.comGAMMA Investing LLC Grows Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 16 at 3:02 AM | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) and Nabriva Therapeutics (NASDAQ:NBRV) Financial SurveyJune 14, 2025 | americanbankingnews.comWedge Capital Management L L P NC Acquires 13,955 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 10, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Two Sigma Investments LPJune 7, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Acquires 11,304 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 5, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.62 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 5, 2025 | marketbeat.comMillennium Management LLC Trims Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCORI, SUPN, IDYA, and CNTA Company DescriptionsCentessa Pharmaceuticals NASDAQ:CNTA$12.68 +0.08 (+0.63%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$13.29 +0.61 (+4.81%) As of 06/18/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Corium International NASDAQ:CORICorium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Corplex Ropinirole, a transdermal patch for the treatment of Parkinson's disease; and Motion Sickness Patch, a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.IDEAYA Biosciences NASDAQ:IDYA$21.86 -0.06 (-0.27%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$21.88 +0.02 (+0.09%) As of 06/18/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Supernus Pharmaceuticals NASDAQ:SUPN$32.96 +0.63 (+1.95%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$32.93 -0.03 (-0.10%) As of 06/18/2025 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
